ROVI CM

Belkins
ROVI provides an answer to the growing trend among pharmaceutical companies to outsource their manufacturing processes. Thus, the Company makes use of the high manufacturing capacity available at its facilities by providing the whole range of manufacturing services: oral and injectables forms.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

news image

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More

GSK COLLABORATES WITH VIR BIOTECHNOLOGY TO FIND CORONAVIRUS SOLUTIONS

HospiMedica International | April 07, 2020

news image

GlaxoSmithKline plc (London, UK) and Vir Biotechnology, Inc. (San Francisco, CA, USA) have entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbr...

Read More

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

news image

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

news image

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More
news image

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More
news image

GSK COLLABORATES WITH VIR BIOTECHNOLOGY TO FIND CORONAVIRUS SOLUTIONS

HospiMedica International | April 07, 2020

GlaxoSmithKline plc (London, UK) and Vir Biotechnology, Inc. (San Francisco, CA, USA) have entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbr...

Read More
news image

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More
news image

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More